10x Genomics Revenue and Competitors

Claim your profile

Location

$242.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • 10x Genomics's estimated annual revenue is currently $459.2M per year.(i)
  • 10x Genomics received $35.0M in venture funding in January 2019.
  • 10x Genomics's estimated revenue per employee is $181,998
  • 10x Genomics's total funding is $242.6M.
  • 10x Genomics's current valuation is $11.6B. (January 2022)

Employee Data

  • 10x Genomics has 2523 Employees.(i)
  • 10x Genomics grew their employee count by 54% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4280M123836%$28M$63.3B
#2
$34.3M17717%$110MN/A

At 10X, we want ambitious, talented software engineers to join us in building revolutionary DNA sequencing technology. Our multi-disciplinary team in microfluidics, biochemistry, mechanical engineering, computational biology, and software has a proven track record of delivering successful commercial products built on deep technological innovation. We are pursuing an enormous potential market with backing from tier-one venture investors. While DNA sequencing technology has advanced rapidly, it's still at a level equivalent to what assembly language was to computing, with huge advances yet to be made. 10X is creating products that will do for sequencing what C did for computing, bringing a leap in higher-order clarity and meaning to what is now very low-level information. Software is a key part of that leap. The scale and complexity of analyzing, managing, and visualizing DNA sequencing data means this is an area with no shortage of hard problems, where brilliant engineering still matters and can yield big payoffs. We want computer scientists and engineers - not just programmers - who excel at creating elegant, practical solutions at every level from web APIs down to LLVM code optimization. We are developing performance-critical algorithms, highly parallel data analysis architectures, robust web applications, and rich user interfaces and visualizations deployed to desktop and cloud on legacy-free stacks. If you are the kind of person who is an avid fan of technology in all fields, not just your own, and want to apply your talent alongside a diverse team of experts every day, join us at 10X.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$242.6M

Total Funding

2523

Number of Employees

$459.2M

Revenue (est)

54%

Employee Growth %

$11.6B

Valuation

N/A

Accelerator

10x Genomics News

2022-04-17 - $113.53 Million in Sales Expected for 10x Genomics, Inc ...

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems...

2022-04-17 - 10x Genomics debuts sample prep kits to expand access to ...

10x Genomics has unveiled two new preparation products designed to expand the range of samples that are compatible with the company's...

2022-04-17 - 10x Genomics Launches Two New Products to Unlock Wider ...

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The...

2019-09-12 - 10x Genomics Prices Initial Public Offering

10x Genomics, Inc., a Pleasonton, Calif.-based company that build products combining hardware, chemistry, and software to give single cell and spatial views of biological systems, priced its initial public offering. Its Class A common stock are offered at a price of $39.00 per share, before und ...

2019-03-20 - Global Single-Cell Genome Sequencing Market 2019 Top

The top contenders Bio-Rad Laboratories, 10x Genomics, Novogene, Fluidigm, BGI, Illumina, Inc., Oxford Nanopore Technologies, Pacific Biosciences, Thermo

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A32959%N/A
#2
$1431.5M3787-1%N/A
#3
$1760M610722%$7M
#4
$1482.2M631613%N/A
#5
$1482.7M7304N/AN/A

10x Genomics Funding

DateAmountRoundLead InvestorsReference
2015-01-13$55.5MBForesite Capital ManagementArticle
2016-03-18$55.0MCFidelity Management & ResearchArticle
2018-04-27$125.0MDMeritech Capital PartnersArticle
2019-01-08$35.0MDMeritech CapitalArticle